Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme

針對症狀 Brain and Central Nervous System Tumors
臨床試驗編號 NCT00331526
臨床階段 Phase II
臨床試驗位址 Hoag Cancer Institute at Hoag Memorial Hospital Presbyterian
目前研究進度 This study has been completed.
試驗開始日期 May 30, 2006
試驗開始日期 October 1, 2011
臨床目的 RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing. Aldesleukin may stimulate the white blood cells, including lymphokine-activated killer cells, to kill tumor cells. Giving cellular adoptive immunotherapy during or after surgery may kill more tumor cells.

PURPOSE: This phase II trial is studying how well cellular adoptive immunotherapy works in treating patients with glioblastoma multiforme.

http://www.clinicaltrial.gov/ct2/show/NCT00331526?term=adoptive+AND+cell+therapy&rank=15